PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein

• Main Authors: Thura, Min, Al-Aidaroos, Abdul Qader, Gupta, Abhishek, Chee, Cheng Ean, Lee, Soo Chin, Hui, Kam Man, Li, Jie, Guan, Yeoh Khay, Yong, Wei Peng, So, Jimmy, Chng, Wee Joo, Ng, Chin Hin, Zhou, Jianbiao, Wang, Ling Zhi, Yuen, John Shyi Peng, Ho, Henry Sun Sien, Yi, Sim Mei, Chiong, Edmund, Choo, Su Pin, Ngeow, Joanne, Ng, Matthew Chau Hsien, Chua, Clarinda, Yeo, Eugene Shen Ann, Tan, Iain Bee Huat, Sng, Joel Xuan En, Tan, Nicholas Yan Zhi, Thiery, Jean Paul, Goh, Boon Cher, Zeng, Qi
• Other Authors: Lee Kong Chian School of Medicine (LKCMedicine)
• Format: Article
• Language: English
• Published: 2019
• Subjects: Antibodies; Cancer Immunotherapy; Science::Medicine
• Online Access: https://hdl.handle.net/10356/79479; http://hdl.handle.net/10220/49728
• Institution: Nanyang Technological University

Tumor-specific antibody drugs can serve as cancer therapy with minimal side effects. A humanized antibody, PRL3-zumab, specifically binds to an intracellular oncogenic phosphatase PRL3, which is frequently expressed in several cancers. Here we show that PRL3-zumab specifically inhibits PRL3+ cancer...